Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current ...
Barchart on MSN
What to expect from Eli Lilly’s Q4 2025 earnings report
Boasting a market cap of $1 trillion, Eli Lilly and Company (LLY) is a major global research-based pharmaceutical company that discovers, develops, manufactures, and markets a broad portfolio of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results